Background Assessing the outcomes of surgeries for hepatocellular carcinoma (HCC)
patients who exceed the Milan criteria is necessary. Some studies have demonstrated that …

AIMS: Alpha-fetoprotein (AFP) loses its potentials in treatment evaluation and prognosis
prediction in patients with AFP negative (≤ 20 ng/ml) hepatocellular carcinoma (HCC). The …

Alpha-fetoprotein (AFP) represents the most important biomarker for hepatocellular
carcinoma (HCC). The aim of this study was to identify the optimal staging system to predict …

Background The value of alpha-fetoprotein (AFP) as a prognostic indicator in patients with
hepatocellular carcinoma (HCC) has been proposed in recent studies, but the evidence so …

Background Serum alpha-fetoprotein (AFP) is frequently used to predict posthepatectomy
outcomes in patients with hepatocellular carcinoma (HCC), but its predictive value is still not …

AIM: To identify the clinical outcomes of hepatocellular carcinoma (HCC) patients with
inconsistent α-fetoprotein (AFP) levels which were initially high and then low at recurrence …

UICC staging) and tumor size. Although this study is retrospective, it is of interest both by the
issue raised which is still contradictory and by the large size of the cohort studied by the …

Abstract Background/Aim: Alpha-fetoprotein (AFP) had been used as a prognostic factor in
hepatocellular carcinoma but it was unknown what level of AFP could predict the survival of …

AIM To investigate whether the change in pre-/post-operation serum alpha-fetoprotein (AFP)
levels is a predictive factor for hepatocellular carcinoma (HCC) outcomes. METHODS We …

Background: Mixed evidence challenges preoperative alpha-fetoprotein (AFP) as an
independent prognostic factor for patients with hepatocellular carcinoma (HCC) after …